Journal Mobile Options
Table of Contents
Vol. 72, No. 3-4, 2007
Issue release date: January 2008
Oncology 2007;72:147–151
(DOI:10.1159/000112731)

Pegylated Liposomal Doxorubicin (Caelyx®) in Metastatic Breast Cancer: A Community-Based Observation Study

Salzberg M. · Thürlimann B. · Hasler U. · Delmore G. · von Rohr A. · Thürlimann A. · Ruhstaller T. · Stopatschinskaja S. · von Moos R.
aPharma Brains, Basel, bKantonsspital, St. Gallen, cKantonsspital, Frauenfeld, dKlinik Hirslanden, Zürich, eEssex Chemie AG, Lucerne, and fKantonsspital Graubünden, Chur, Switzerland

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objectives: Pegylated liposomal doxorubicin (PLD) has improved therapy options significantly, as it causes less myelosuppression, nausea, vomiting, and alopecia than conventional doxorubicin, while maintaining efficacy. The goal of this survey was to determine whether the use of PLD in a community-based patient group is comparable regarding chemotherapeutic doses and side effects to preselected study patients. Methods: 100 questionnaires were randomly sent to Swiss oncologists in private practices, general hospitals and university hospitals. Results: The patient cohort was heterogeneous with respect to prior treatments. PLD was an active agent in metastatic breast cancer and was well tolerated by the majority of patients. The most common non-hematological side effects were hand-foot syndrome (HFS) and mucositis while only patients receiving a dose of 50 mg/m2 (recommended dose) experienced grade 4 HFS. The reported mean dose of PLD was 38.5 mg/m2. Conclusions: This community-based observational study supports previous reports indicating that PLD at a median dose of ≤40 mg/m2 every 4 weeks is an active, well-tolerated agent in non-selected, pretreated patients with metastatic breast cancer.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Lutz JM, Francisci S, Mugno E, Usel M, Pompe-Kirn V, Coebergh JW, Bieslka-Lasota M; EUROPREVAL Working Group: Cancer prevalence in Central Europe: the EUROPREVAL Study. Ann Oncol 2003;14:313–322.
  2. Chia S, Speers C, Kang A, et al: The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population-based cohort. Proc Am Soc Clin Oncol 2003;22:6.
  3. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A: Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women (review). J Clin Oncol 1998;16:3439–3460.
  4. Jones D, Ghersi D, Wilcken N: Addition of drug/s to a chemotherapy regimen for metastatic breast cancer (review). Cochrane Database Syst Rev 2006;3:CD003368.
  5. Rivera E: Liposomal anthracyclines in metastatic breast cancer: clinical update. Oncologist 2003;8(suppl 2):3–9.
  6. O’Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C; CAELYX Breast Cancer Study Group: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440–449.
  7. Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, Vogel CL, Kaufmann M, von Minckwitz G, Henderson IC, Mellars L, Alland L, Tendler C: Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004;22:3893–3901.
  8. Robert NJ, Vogel CL, Henderson IC, Sparano JA, Moore MR, Silverman P, Overmoyer BA, Shapiro CL, Park JW, Colbern GT, Winer EP, Gabizon AA: The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer (review). Semin Oncol 2004;31(suppl 13): 106–146.

    External Resources

  9. Gabizon AA: Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001;19:424–436.
  10. Symon Z, Peyser A, Tzemach D, Lyass O, Sucher E, Shezen E, Gabizon A: Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 1999;86:72–78.
  11. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A: Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995;13:1777–1785.
  12. Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, Gabizon A: Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000;89:1037–1047.
  13. Pritchard KI, Shepherd LE, O’Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN; National Cancer Institute of Canada Clinical Trials Group: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:2103–2111.
  14. O’Brien ME, Leonard RC, Barrett-Lee PJ, Eggleton SP, Bizzari JP: Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. UK Study Group. Ann Oncol 1999;10:205–210.
  15. Chia S, Clemons M, Martin LA, Rodgers A, Gelmon K, Pond GR, Panasci L: Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 2006;24:2773–2778.
  16. Ranson MR, Carmichael J, O’Byrne K, Stewart S, Smith D, Howell A: Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997;15:3185–3591.
  17. Al-Batran SE, Bischoff J, von Minckwitz G, Atmaca A, Kleeberg U, Meuthen I, Morack G, Lerbs W, Hecker D, Sehouli J, Knuth A, Jager E: The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br J Cancer 2006;94:1615–1620.
  18. Coleman RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P, Batter V, Ngalula-Kabanga E, Dittrich C, Piccart M: A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer 2006;42:882–887.
  19. Amantea M, Newman MS, Sullivan TM, Forrest A, Working PK: Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs. Hum Exp Toxicol 1999;18:17–26.
  20. Rose PG, Maxson JH, Fusco N, Mossbruger K, Rodriguez M: Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol 2001;82:323–328.
  21. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J: Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 2000;78:369–372.
  22. Al-Batran SE, Meerpohl HG, von Minckwitz G, Atmaca A, Kleeberg U, Harbeck N, Lerbs W, Hecker D, Sehouli J, Knuth A, Jager E: Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology 2006;70:141–146.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50